<DOC>
	<DOCNO>NCT00928330</DOCNO>
	<brief_summary>This multicenter , Phase Ib study open label , dose escalation , three-arm study evaluate safety , tolerability , pharmacokinetics , activity oral ( PO ) GDC 0941 administer combination either intravenous ( IV ) infusion T-DM1 IV infusion trastuzumab .</brief_summary>
	<brief_title>Trastuzumab Trastuzumab-MCC-DM1 Administered Intravenously GDC-0941 Administered Orally Patients With HER2-Positive Metastatic Breast Cancer Who Have Progressed Previous Trastuzumab-Based Therapy</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Ado-trastuzumab emtansine</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Maytansine</mesh_term>
	<criteria>Histologically document locally advanced metastatic breast cancer progress least one trastuzumabbased regimen metastatic locally advanced set HER2positive disease document one follow result use FDAapproved test method : FISHpositive , chromogenic situ hybridization ( CISH ) positive , IHC 3 + local laboratory assessment Life expectancy &gt; = 90 day Agreement use effective form contraception duration study History Grade &gt; = 3 hypersensitivity reaction trastuzumab , Grade &gt; = 1 recent trastuzumab infusion study entry , continue requirement prolong trastuzumab infusion prevent hypersensitivity reaction History intolerance trastuzumab and/or adverse event relate trastuzumab result trastuzumab permanently discontinue Prior anticancer therapy ( e.g. , biologic target therapy , chemotherapy , hormonal therapy ) within 2 week prior Day 1 Prior investigational anticancer therapy within 4 week prior Day 1 Grade &gt; = 2 peripheral neuropathy History Grade &gt; = 3 hyperglycemia ( fast ) History Type 1 Type 2 diabetes require daily medication History clinically significant cardiac pulmonary dysfunction History malabsorption syndrome condition would interfere enteral absorption Clinically significant history liver disease , include cirrhosis , current alcohol abuse , current know active infection HIV , hepatitis B virus , hepatitis C virus Any condition require anticoagulant , warfarin , heparin , thrombolytic agent Any condition require &gt; 2 gram acetaminophen daily Need current chronic corticosteroid therapy Pregnancy , lactation , breastfeed Current severe , uncontrolled systemic disease ( e.g. , clinically significant cardiovascular , pulmonary , metabolic disease ) Major surgical procedure significant traumatic injury within 28 day prior Day 1 , anticipation need major surgery course study treatment Symptomatic hypercalcemia require continue use bisphosphonate therapy Known brain metastasis untreated , symptomatic , require therapy control symptom</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>TDM-1</keyword>
	<keyword>HER2</keyword>
	<keyword>HER2+</keyword>
	<keyword>HER2+ Breast Cancer</keyword>
	<keyword>HER-2</keyword>
	<keyword>MBC</keyword>
	<keyword>Trastuzumab emtansine</keyword>
</DOC>